CXCR4 and hepatocellular carcinoma: Meanwhile, novel approaches such as CXCR4/CXCL12 axis inhibitors and nanoparticle-based drug delivery systems are being explored to selectively target TAMs and improve ICI efficacy in HCC [22–24].